These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 11785852

  • 1. Clinical management of respiratory tract infections in the community: experience with telithromycin.
    Quintiliani R.
    Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
    [Abstract] [Full Text] [Related]

  • 2. Clinical efficacy of new antibacterial therapies in at-risk populations.
    Lorenz J.
    J Infect; 2002 Feb; 44 Suppl A():25-30. PubMed ID: 12150492
    [Abstract] [Full Text] [Related]

  • 3. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults.
    Carbon C.
    Infection; 2003 Oct; 31(5):308-17. PubMed ID: 14556055
    [Abstract] [Full Text] [Related]

  • 4. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J.
    Int J Clin Pract; 2003 Oct; 57(6):519-29. PubMed ID: 12918892
    [Abstract] [Full Text] [Related]

  • 5. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D.
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [Abstract] [Full Text] [Related]

  • 6. Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review.
    Fogarty CM, Buchanan P, Aubier M, Baz M, van Rensburg D, Rangaraju M, Nusrat R.
    Int J Infect Dis; 2006 Mar; 10(2):136-47. PubMed ID: 16183318
    [Abstract] [Full Text] [Related]

  • 7. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies.
    Low DE, Brown S, Felmingham D.
    Clin Microbiol Infect; 2004 Jan; 10(1):27-36. PubMed ID: 14706083
    [Abstract] [Full Text] [Related]

  • 8. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
    Fogarty CM, Kohno S, Buchanan P, Aubier M, Baz M.
    J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
    [Abstract] [Full Text] [Related]

  • 9. Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
    Felmingham D, Zhanel G, Hoban D.
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():33-42. PubMed ID: 11566974
    [Abstract] [Full Text] [Related]

  • 10. The ketolides: a critical review.
    Zhanel GG, Walters M, Noreddin A, Vercaigne LM, Wierzbowski A, Embil JM, Gin AS, Douthwaite S, Hoban DJ.
    Drugs; 2002 Sep; 62(12):1771-804. PubMed ID: 12149046
    [Abstract] [Full Text] [Related]

  • 11. Barriers to the effective management of respiratory tract infections in the community.
    Saginur R.
    Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
    [Abstract] [Full Text] [Related]

  • 12. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003-2004).
    Blasi F, Farrell DJ, Dubreuil L.
    Diagn Microbiol Infect Dis; 2009 Mar; 63(3):302-8. PubMed ID: 19135821
    [Abstract] [Full Text] [Related]

  • 13. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
    Casellas JM, Visser M, Mac Dougall N, Coco B, Tomé G, Gliosca L, Grupo Colaborativo de Telitromicina del Cono Sur.
    Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
    [Abstract] [Full Text] [Related]

  • 14. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L.
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [Abstract] [Full Text] [Related]

  • 15. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
    Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B.
    J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
    [Abstract] [Full Text] [Related]

  • 16. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections.
    Yassin HM, Dever LL.
    Expert Opin Investig Drugs; 2001 Feb; 10(2):353-67. PubMed ID: 11178347
    [Abstract] [Full Text] [Related]

  • 17. Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens.
    Hammerschlag MR, Roblin PM, Bébéar CM.
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():25-31. PubMed ID: 11566973
    [Abstract] [Full Text] [Related]

  • 18. Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections.
    Low DE, Felmingham D, Brown SD, Rangaraju M, Nusrat R.
    J Infect; 2004 Aug; 49(2):115-25. PubMed ID: 15236918
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.